Molecular mechanism of benzo [a] pyrene regulating lipid metabolism via aryl hydrocarbon receptor. 2022

Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
Department of Pharmacology of Pharmaceutical College, Inner Mongolia Medical University, Hohhot, 010010, China.

BACKGROUND Benzo [a] pyrene (BaP), a potent carcinogen, has been proved that it has toxicological effects via activation the aryl hydrocarbon receptor (AhR) pathway. AhR can participate in regulating lipogenesis and lipolysis. This topic will verify whether BaP regulates lipid metabolism via AhR. METHODS (1) C57BL/6 mice were gavaged with BaP for 12 weeks to detect serum lipids, glucose tolerance, and insulin resistance. Morphological changes in white adipose tissue (WAT) were detected by Hematoxylin and Eosin staining. The mRNA expression levels of adipogenesis-related factors included recombinant human CCAAT/enhancer binding protein alpha (C/EBPα), peroxisome proliferator-activated receptor gamma (PPARγ), and fatty acid binding protein 4 (FABP4) and inflammatory factors included nuclear factor kappa-B (NF-κB), monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor alpha (TNF-α) were detected using PCR. (2) Neutral lipid content changes in differentiated 3 T3-L1 adipocytes treated with BaP with and w/o AhR inhibitor were detected by Oil red staining. The protein expression levels of adipogenesis- and decomposition-related factors included PPARγ coactivator-1 alpha (PGC-1α), and peroxisome proliferation-activated receptor alpha (PPARα) were detected using western blotting. The mRNA expression levels of inflammatory factors were detected using PCR. RESULTS (1) BaP inhibited body weight gain, decreased lipid content, increased lipid levels, and decreased glucose tolerance and insulin tolerance in mice; (2) BaP reduced the expressions of C/EBPα, PPARγ, FABP4, PGC-1α, and PPARα and increased the expressions of NF-κB, MCP-1, and TNF-α by activating AhR. CONCLUSIONS BaP inhibit fat synthesis and oxidation while inducing inflammation by activating AhR, leading to WAT dysfunction and causing metabolic complications.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001564 Benzo(a)pyrene A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke. 3,4-Benzopyrene,3,4-Benzpyrene,3,4 Benzopyrene,3,4 Benzpyrene
D017667 Adipocytes Cells in the body that store FATS, usually in the form of TRIGLYCERIDES. WHITE ADIPOCYTES are the predominant type and found mostly in the abdominal cavity and subcutaneous tissue. BROWN ADIPOCYTES are thermogenic cells that can be found in newborns of some species and hibernating mammals. Fat Cells,Lipocytes,Adipocyte,Cell, Fat,Cells, Fat,Fat Cell,Lipocyte
D050356 Lipid Metabolism Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS. Metabolism, Lipid
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
June 2007, Toxicology,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
January 2000, Proceedings of the National Academy of Sciences of the United States of America,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
January 2018, American journal of cancer research,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
January 1980, Annals of the New York Academy of Sciences,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
April 2016, Environmental toxicology and pharmacology,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
May 2009, Toxicological sciences : an official journal of the Society of Toxicology,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
August 1981, Journal of the National Cancer Institute,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
August 1974, Nature,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
January 1978, Biochemical pharmacology,
Wei Lou, and Meng-di Zhang, and Qi Chen, and Tu-Ya Bai, and Yu-Xia Hu, and Feng Gao, and Jun Li, and Xiao-Li Lv, and Qian Zhang, and Fu-Hou Chang
January 1979, Pharmacology & therapeutics. Part B: General & systematic pharmacology,
Copied contents to your clipboard!